Summit Therapeutics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 12.4× Summit Therapeutics Inc's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| SMMT | VGT | |
|---|---|---|
Market Cap | $13.71B | $170.20B |
Volume | 6,173,057 | 5,132,883 |
Sector | Health | — |
52-Week High | $26.38 | $129.79 |
52-Week Low | $12.43 | $83.59 |
Typical Hold Time | 16 Days | 129 Days |
Enterprise Value | $13.04B | — |
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
VGT trades at $127.98, down 1.07% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong historical performance and appeal for long-term growth, with a focus on technology sector exposure. The ETF's low expense ratio and concentration in top tech names like Nvidia, Apple, and Microsoft are key attractions.
Outlook remains positive given tech sector momentum, but risks include high concentration in a few stocks and sensitivity to AI growth trends. Dividend yield is minimal, emphasizing capital appreciation over income. Investors should weigh sector volatility against long-term growth potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →